Journal of Current Glaucoma Practice最新文献

{"title":"Glaucoma and Driving License: How to Identify Patients at Risk of Revocation.","authors":"Luca Landini,&nbsp;Simone Donati,&nbsp;Maurizio Digiuni,&nbsp;Sara Feltre,&nbsp;Gabriele Corsini,&nbsp;Elias Premi,&nbsp;Paolo Radice,&nbsp;Claudio Azzolini","doi":"10.5005/jp-journals-10078-1379","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1379","url":null,"abstract":"<p><strong>Aim: </strong>To identify clinical criteria that are easily achievable with follow-up tests and can identify subjects not suitable for driving.</p><p><strong>Patients and methods: </strong>We recruited 194 subjects with a clear diagnosis of glaucoma, with no other conditions that could affect the visual field (VF), and who performed a reliable VF examination. All patients underwent a full ophthalmologic evaluation and a questionnaire considering driving habits. An integrated visual field (IVF) was built using both monocular VF charts; the number of missed points (NoMP) within the central 20°, the average sensitivity (AS), and the better eye mean deviation (BEMD) were evaluated.</p><p><strong>Results: </strong>A total of 128 subjects showed a valid driving license (DL); 61.7% of drivers did not show missed points within the central 20° of the IVF, 27.4% presented one to three missed points, and 10.9% had four or more missed points. Best corrected visual acuity (BCVA) was highly above the legal criteria.Stratifying drivers by their BEMD (-7, -10, and -14 dB), we confirmed that the BEMD decrease corresponds to an increased NoMP and a decreased AS.</p><p><strong>Conclusion: </strong>Better eye mean deviation can be useful in clinical practice to identify patients at increased risk of being unsuitable for driving. Nevertheless, it is important to set specific cut-offs based on on-road driving performance. IVF evaluation may also be implemented in perimeter analysis software so that the composition of IVF, the BEMD, and the AS could directly describe the patient's binocular VF, excluding recourse to the Esterman visual field test (EVFT).</p><p><strong>Clinical significance: </strong>This new methodology will allow every physician-not just ophthalmologists-even if not an expert in evaluating a VF test, in assessing the ability to drive of glaucomatous patients.</p><p><strong>How to cite this article: </strong>Landini L, Donati S, Digiuni M, <i>et al.</i> Glaucoma and Driving License: How to Identify Patients at Risk of Revocation. J Curr Glaucoma Pract 2022;16(2):117-123.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"117-123"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/b2/jocgp-16-117.PMC9452703.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40373761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Onset Neovascular Glaucoma due to COVID-19-related Retinopathy.","authors":"Manoj Soman,&nbsp;Asmita Indurkar,&nbsp;Thomas George,&nbsp;Jay U Sheth,&nbsp;Unnikrishnan Nair","doi":"10.5005/jp-journals-10078-1356","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1356","url":null,"abstract":"<p><strong>Aim: </strong>To present a case of rapid onset on neovascular glaucoma following the Coronavirus disease 2019 (COVID-19).</p><p><strong>Background: </strong>COVID-19 has various ocular manifestations such as conjunctivitis, uveitis, retinal vasculitis, and so on. However, to date, the development of neovascular glaucoma has not been reported in COVID-19.</p><p><strong>Case description: </strong>A 50-year-old male with a history of COVID-19 3 weeks ago presented with left eye (OS) central retinal artery occlusion (CRAO) and right eye (OD) cystoid macular edema with disc and microvascular leakage on multimodal imaging. After being managed conservatively for 2 weeks, the patient developed OD neovascular glaucoma with intraocular pressure (IOP) of 44 mm Hg and angle neovascularization (NVA) on gonioscopy. The patient was started on topical antiglaucoma medications (AGM) with panretinal photocoagulation (PRP) and responded well with complete regression of NVA, CME, and normal IOP after 3 weeks.</p><p><strong>Conclusion: </strong>This is the first reported case of rapid onset of NVG secondary to COVID-19-induced retinal vasculitis. COVID-19-associated prothrombotic state with secondary retinal vascular involvement can potentially trigger such NVG. Such NVG responds well with topical AGM and PRP therapy.</p><p><strong>Clinical significance: </strong>Given the global COVID-19 pandemic, it is imperative to be vigilant regarding the various vision-threatening manifestations associated with the disease such as the NVG.</p><p><strong>How to cite this article: </strong>Soman M, Indurkar A, George T, <i>et al.</i> Rapid onset Neovascular Glaucoma due to COVID-19-related Retinopathy. J Curr Glaucoma Pract 2022;16(2):136-140.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"136-140"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2e/54/jocgp-16-136.PMC9452705.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40374321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of the XEN45 Implant in Advanced to End-stage Glaucoma Patients.","authors":"Isaac Hindi,&nbsp;Eran Berkowitz,&nbsp;Inbar Waizer,&nbsp;Beatrice Tiosano","doi":"10.5005/jp-journals-10078-1364","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1364","url":null,"abstract":"<p><strong>Purpose: </strong>To report the efficacy of the XEN45 implant in advanced to end-stage glaucoma patients, after a 6 months follow-up.</p><p><strong>Methods: </strong>Retrospective, noncomparative electronic health record audit of patients who had undergone an XEN45 procedure. The main outcome measures were intraocular pressure (IOP) reduction and the number of antihypertensive medications. Secondary outcome measures were the rates of early postoperative complications. Complete and qualified success; failure and hypotony were defined according to the World Glaucoma Association guidelines (Shaarawy TM et al.). Needling rates and short-term complications were assessed and a subgroup analysis was performed.</p><p><strong>Results: </strong>A total of 39 eyes with advanced to end stage-glaucoma were included. Twenty eyes (51%) had undergone combined cataract surgery and 19 (49%), the XEN45 procedure alone. Mean IOP decreased from 19.67 ± 7.87 mm Hg to 13.18 ± 6.09 mm Hg; the number of medications decreased from a median use of 4 (IQR 2-5) to 0 (IQR 0-1). Complete success was achieved in 24 (61.5%) of the eyes, qualified success in 10 (25.6%), and failure in five (12.82%). Needling was required in 15 (38.46%) of the eyes at 6 months. Choroidal detachment occurred in eight (20.51%) eyes, numerical hypotony (IOP ≤ 5 mm Hg) at day 1 was noted in seven (17.95%) eyes with a full resolution by 2 weeks.</p><p><strong>Conclusion: </strong>In this short-term follow-up, we have seen that XEN45 is a viable, effective, and safe procedure utilized in advanced to end-stage glaucoma patients. Treating cases of significant hypotony using AC reformation with sulfur hexafluoride (SF6) is a safe and effective procedure.</p><p><strong>How to cite this article: </strong>Hindi I, Berkowitz E, Waizer I, <i>et al.</i> Efficacy of the XEN45 Implant in Advanced to End-stage Glaucoma Patients. J Curr Glaucoma Pract 2022;16(2):84-90.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"84-90"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7b/be/jocgp-16-84.PMC9452713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Juvenile Xanthogranuloma Presented with Buphthalmos and Corneal Clouding in Neonatal Period: A Case Report.","authors":"Volkan Dericioglu,&nbsp;Mehmet Orkun Sevik,&nbsp;Muhsin Eraslan,&nbsp;Begüm Dirican,&nbsp;Deniz Yücelten,&nbsp;Leyla Cinel","doi":"10.5005/jp-journals-10078-1369","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1369","url":null,"abstract":"<p><strong>Aim: </strong>To report an ocular juvenile xanthogranuloma (JXG) case presented with buphthalmos, corneal cloudiness, and normal intraocular pressure (IOP) in the neonatal period and treated with Ahmed glaucoma valve (AGV) implantation.</p><p><strong>Background: </strong>JXG is a rare disorder predominantly seen in infants, but the neonatal presentation is extraordinary. Although spontaneous hyphema is a common presenting sign in JXG, buphthalmos and corneal opacity in the neonatal period were reported only in one case, which had high IOP values at presentation.</p><p><strong>Case presentation: </strong>Sixteen-day-old male patient presented with buphthalmos, diffuse corneal clouding, and 11 mm Hg of IOP value in the right eye. IOP increased to 28 mm Hg three weeks later, and spontaneous hyphema developed, which did not respond to antiglaucomatous medications and topical corticosteroids. AGV was implanted, and the IOP decreased to 13 mm Hg postoperatively. In the follow-ups, numerous firm yellowish nodules were noticed on the patient's skin during the examination under general anesthesia. Histopathological examination of the skin nodules was compatible with the diagnosis of JXG. Lens subluxation and phacodonesis were developed during the follow-up and were managed with pars plana lensectomy. After a silent period of 3 months, epithelial ingrowth was determined around the side port entrance. Unfortunately, the ingrowth did not respond to cryotherapy and resulted in phthisis bulbi. Pathological evaluation of the enucleated phthisic eye revealed posterior segment involvement.</p><p><strong>Conclusion: </strong>Ocular JXG can be present with buphthalmos, corneal opacity, and normal IOP values without any skin lesions in the neonatal period. Neonatal presentation of JXG may be associated with limited medical therapy response and aggressive disease course.</p><p><strong>Clinical significance: </strong>This case report introduces the second ocular JXG case, which presented with buphthalmos and corneal cloudiness, and the third pathologically proven posterior segment involvement of JXG in the literature.</p><p><strong>How to cite this article: </strong>Dericioglu V, Sevik MO, Eraslan M, <i>et al.</i> Juvenile Xanthogranuloma Presented with Buphthalmos and Corneal Clouding in Neonatal Period: A Case Report. J Curr Glaucoma Pract 2022;16(2):128-131.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"128-131"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/ad/jocgp-16-128.PMC9452710.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40372298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year Outcomes of XEN Implantation with Minimal Bleb Needling.","authors":"Zaria C Ali,&nbsp;Nadeem Moshin,&nbsp;Mohamad T Hakim,&nbsp;Vikas Shankar","doi":"10.5005/jp-journals-10078-1363","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1363","url":null,"abstract":"<p><strong>Aim: </strong>Our study aims to report the 2 years outcomes of the XEN implant in a single unit, single surgeon setting with minimal bleb needling.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted. Inclusion criteria were patients who underwent implantation with a XEN device between May 2016 and December 2017. This included patients who underwent both combined phacoemulsification and intraocular lens implantation alongside XEN implantation and those who underwent XEN implantation alone. Data gathered included basic demographic data, best-corrected visual acuity (LogMAR), intraocular pressure (IOP) in mm Hg, mean deviation from their visual field test, and the number of IOP-lowering medications they were on. This information was recorded for their preoperative visit, and then at 6, 12, 18 and 24 months postoperatively. The primary outcome assessed was a complete success when the patient was without glaucoma medications and had an IOP of 18 mm Hg or less, but more importantly, this also had to equate to a 20% reduction in IOP compared to baseline. Qualified success was defined as the same change in IOP but with medications. Surgical failure is defined as those who required additional glaucoma surgery or those who did not obtain an IOP of 18 mm Hg alongside a 20% reduction in IOP compared to baseline.</p><p><strong>Results: </strong>At 24 months follow-up 82.5% of patients were surgical successes. Complete surgical success was achieved in 27% of patients. Qualified surgical success was achieved in 55.6% of patients. Subgroup analysis of those undergoing XEN implantation on its own and those combined with phacoemulsification + IOL were similar. The rate of bleb needling was low at 4.5%. Complication rates were acceptable at 9.5%.</p><p><strong>Conclusion: </strong>It is possible to get good IOP control with minimal postoperative bleb needling in patients who have undergone XEN implantation. Similar success rates are found in those undergoing combined procedures.</p><p><strong>Clinical significance: </strong>Bleb needling carries its own risks. Minimizing the number of bleb needling allows procedures to be reserved at a later date. Furthermore, our study shows that success rates are not affected by doing a combined procedure with phacoemulsification.</p><p><strong>How to cite this article: </strong>Ali ZC, Moshin N, Hakim MT, <i>et al.</i> Two-year Outcomes of XEN Implantation with Minimal Bleb Needling. J Curr Glaucoma Pract 2022;16(2):79-83.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"79-83"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/f5/jocgp-16-79.PMC9452704.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40373187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pattern Electroretinogram Parameters and their Associations with Optical Coherence Tomography in Glaucoma Suspects.","authors":"Andrew Tirsi,&nbsp;Amanda Wong,&nbsp;Daniel Zhu,&nbsp;Guillaume Stoffels,&nbsp;Peter Derr,&nbsp;Celso Tello Md","doi":"10.5005/jp-journals-10078-1365","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1365","url":null,"abstract":"<p><strong>Aim: </strong>To investigate whether steady state pattern electroretinogram (ssPERG) could identify retinal ganglion cell (RGC) dysfunction, and to assess the relationship between ssPERG with optical coherence tomography (OCT) measurements in glaucoma suspects (GS).</p><p><strong>Materials and methods: </strong>This was a prospective cohort study of GS, identified based on suspicious optic disk appearance and glaucoma risk factors. Complete eye exam, Standard automated perimetry, OCT, and ssPERG were performed. Magnitude (Mag), Magnitude D (MagD), and MagD/Mag ratio were subsequently used in the correlation and linear regression analyses between ssPERG parameters and the RNFL, GCL/IPL, and macular thicknesses measurements.</p><p><strong>Results: </strong>Forty-nine eyes of 26 patients were included. Mag and MagD were significantly correlated with the superior, inferior, and average RNFL thicknesses (avRNFLT). All ssPERG parameters were significantly correlated with the average and minimum GCL/IPL thicknesses and the inner macular sector thicknesses. Mag and MagD significantly predicted the superior, inferior, and avRNFLT in the regression analysis. All ssPERG parameters were predictive of GCL/IPL thickness in all sectors as well as the average and minimum GCL/IPL thicknesses. All ssPERG parameters were predictive of all inner macular sector thicknesses and MagD was also predictive of some outer macular sector thicknesses as well.</p><p><strong>Conclusion: </strong>ssPERG has significant correlations with and is predictive of RNFL, GCL/IPL, and macular thicknesses in glaucoma suspects.</p><p><strong>Clinical significance: </strong>ssPERG may serve as a useful objective functional tool for identifying and following the progression of disease in glaucoma suspects.</p><p><strong>How to cite this article: </strong>Tirsi A, Wong A, Zhu D, <i>et al.</i> Pattern Electroretinogram Parameters and their Associations with Optical Coherence Tomography in Glaucoma Suspects. J Curr Glaucoma Pract 2022;16(2):96-104.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"16 2","pages":"96-104"},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/95/9e/jocgp-16-96.PMC9452702.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40373762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Pilot Study Assessing Treatment Outcomes in Neovascular Glaucoma Using Ahmed Glaucoma Valve with and without Cyclophotocoagulation.","authors":"Richard L Ford, O'Rese J Knight, Meredith R Klifto, Alice Yang Zhang, Christopher A Wiesen, David Fleischman","doi":"10.5005/jp-journals-10078-1358","DOIUrl":"10.5005/jp-journals-10078-1358","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this retrospective pilot study was to examine the short-term effect of simultaneous Ahmed Glaucoma Valve implantation and cyclophotocoagulation on postoperative outcomes in patients with neovascular glaucoma.</p><p><strong>Methods and materials: </strong>Patient charts were selected for inclusion in this study if they carried a diagnosis of neovascular glaucoma and underwent Ahmed glaucoma valve implantation only, Ahmed glaucoma valve implantation with cyclophotocoagulation, or cyclophotocoagulation only. A total of 55 eyes of 54 patients were selected for data collection and analysis. Main outcome measures included 1-, 3-, and 6-month intraocular pressure and occurrence of the hypertensive phase. Other outcomes included visual acuity, surgical complication rate, and a number of 6-month postoperative ophthalmic medications.</p><p><strong>Results: </strong>A significantly lower intraocular pressure was seen in the group that received Ahmed glaucoma valve implantation + cyclophotocoagulation compared to the Ahmed glaucoma valve-only group at 3 and 6 months (<i>p</i> = 0.03 and <0.001, respectively). The difference in the occurrence of the hypertensive phase between the Ahmed glaucoma valve-only group and the Ahmed glaucoma valve + cyclophotocoagulation group approached but did not reach significance (<i>p</i> = 0.052). A significantly lower intraocular pressure was also seen in the cyclophotocoagulation-only group compared to the Ahmed glaucoma valve-only group at 3 months (<i>p</i> = 0.006).</p><p><strong>Conclusion: </strong>Simultaneous Ahmed glaucoma valve implantation and cyclophotocoagulation significantly lowered intraocular pressure at 3 and 6 months compared to Ahmed glaucoma valve implantation alone in patients with neovascular glaucoma.</p><p><strong>Clinical significance: </strong>Neovascular glaucoma is difficult to manage medically and surgically. When surgery is performed, intraocular pressure often remains elevated postoperatively despite aggressive medical management. This study examines a novel method to lower intraocular pressure after Ahmed glaucoma valve implantation in patients with neovascular glaucoma.</p><p><strong>How to cite this article: </strong>Ford RL, Knight ORJ, Klifto MR, <i>et al.</i> A Pilot Study Assessing Treatment Outcomes in Neovascular Glaucoma Using Ahmed Glaucoma Valve with and without Cyclophotocoagulation. J Curr Glaucoma Pract 2022;16(1):4-10.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":" ","pages":"4-10"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/85/jocgp-16-4.PMC9385394.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40349758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year Outcomes Following Internal Ligation Suture Removal in 350 mm² Baerveldt Tube Implant Surgery.","authors":"Francesco Stringa,&nbsp;Ruth Chen,&nbsp;Pavi Agrawal","doi":"10.5005/jp-journals-10078-1351","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1351","url":null,"abstract":"<p><strong>Aim: </strong>Long-term data of the postoperative management following Baerveldt tube surgery (BVT) is currently limited. This study aims to evaluate the outcome and the safety profile of internal ligation suture removal after BVT surgery for refractory glaucoma.</p><p><strong>Materials and methods: </strong>A prospective, consecutive, non-comparative case series of patients previously undergoing BVT 350 mm² surgery with 0.4 mg/mL mitomycin C (MMC), 3/0 intraluminal suture (Supramid) insertion, and 10/0 nylon external ligation suture(s). For each patient, data was collected over 12 months after internal ligation suture removal. Follow-up assessments looked at intraocular pressure (IOP), complication rate, and postoperative number of glaucoma medications. Definition of success was adopted as per the World Glaucoma Association recommendations.</p><p><strong>Results: </strong>Twenty-four patients were included. On average, Supramid was removed at 22 ± 18.2 weeks following BVT surgery. Preoperatively, the mean IOP was 30.9 ± 12.6 mm Hg and the average antiglaucoma medications were 1.95 ± 1.13. At 12 months, the mean IOP was 15.2 ± 5.3 mm Hg and the mean number of glaucoma medications was 1.3 ± 0.2. Qualified success with IOP ≤ 21 mm Hg and IOP ≤ 15 mm Hg was achieved in 62.5% and 33.3%, respectively. Only two patients developed hypotony following Supramid removal; both resolved spontaneously within 1 month.</p><p><strong>Conclusion: </strong>Our results show a good IOP reduction and safety profile at 1 year from internal ligation suture removal following BVT. A drop in IOP of approximately 50% from the preoperative IOP can be expected.</p><p><strong>How to cite this article: </strong>Stringa F, Chen R, Agrawal P. One-year Outcomes Following Internal Ligation Suture Removal in 350 mm² Baerveldt Tube Implant Surgery. J Curr Glaucoma Pract 2022;16(1):20-23.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":" ","pages":"20-23"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/a2/jocgp-16-20.PMC9385391.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40349760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vision-related Quality of Life in Congolese Patients with Glaucoma.","authors":"Isis K Kapinga,&nbsp;David L Kayembe,&nbsp;Jean-Claude Mwanza","doi":"10.5005/jp-journals-10078-1360","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1360","url":null,"abstract":"Abstract Purpose To assess the vision-related quality of life (QoL) in Congolese patients with glaucoma and its associated factors. Methods Ninety-four patients with open-angle glaucoma and 42 age-matched controls were included in the study. QoL was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). QoL scores were compared between patients and controls. Correlation analysis was run to assess the association of QoL scores with visual function measures. Multivariate linear regression analyses were used to identify demographic and clinical factors that independently predict the overall QoL and its subdomains. Results The QoL composite score (QoL-CS) of glaucoma patients (60.2 ± 30.5) was 31.7% lower than that of controls (87.9 ± 9.5), p < 0.001. QoL subdomain scores were also significantly lower in glaucoma patients than controls (all p < 0.001), with a reduction rate oscillating between 16.5% for color vision and 61.1% for general health. Best-corrected visual acuity (BCVA) of both better seeing eye (BSE) and worst seeing eye (WSE) correlated significantly with QoL-CS (variance: 50.4% and 42.3%, respectively). The correlations of QoL-CS with BSE (variance: 12.9%) and WSE (variance: 16.8%) visual field MD were also significant, but the strengths were weaker than those of BCVA. Every increase of BSE's BCVA by one line improved QoL-CS by 43.4. Conclusion Vision-related quality of life in glaucoma patients is significantly impaired in Congolese patients with glaucoma, starting in the early stage of the disease. BCVA of the BSE emerged as an independent significant predictor of overall QoL and most of its components. How to cite this article Kapinga IK, Kayembe DL, Mwanza JC. Vision-related Quality of Life in Congolese Patients with Glaucoma. J Curr Glaucoma Pract 2022;16(1):24-30.","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":" ","pages":"24-30"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/99/jocgp-16-24.PMC9385387.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40348248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Long-term Clinical Study to Evaluate AGV with Concurrent Intravitreal Ranibizumab vs Primary AGV Implantation in Cases of Refractory Neovascular Glaucoma.","authors":"Jaya Kaushik,&nbsp;Jitendra Ks Parihar,&nbsp;Rakesh Shetty,&nbsp;Ankita Singh,&nbsp;Piyush Chaturvedi","doi":"10.5005/jp-journals-10078-1355","DOIUrl":"https://doi.org/10.5005/jp-journals-10078-1355","url":null,"abstract":"<p><strong>Purpose: </strong>This study was aimed to gauge the efficacy of primary AGV implantation with concurrent intraoperative intravitreal ranibizumab vs primary AGV implantation alone in the management of neovascular glaucoma (NVG).</p><p><strong>Methods: </strong>This retrospective comparative study was carried out based on the data collected in patients of neovascular glaucoma who underwent Ahmed Glaucoma Valve implantation with or without concurrent intravitreal ranibizumab between the period from Feb 2009 to Feb 2015 involving two groups of 40 patients each, having the clinical diagnosis of neovascular glaucoma, having undergone pan-retinal photocoagulation with minimum 03 intravitreal injections of ranibizumab not less than 4 weeks prior to undergoing primary Ahmed glaucoma valve implantation and allotted randomly to either group to receive concurrent administration of intravitreal ranibizumab with Ahmed glaucoma valve (AGV) implant surgery or AGV implant surgery alone. The minimum qualifying follow-up was 3-years. The functional outcome measures included intraoperative and postoperative complications, intraocular pressure (IOP), and the need for antiglaucoma medication, if any, as well as best corrected visual acuity.</p><p><strong>Results: </strong>Both the groups showed a significant decrease in IOP (<i>p</i> < 0.05). Sight and IOP threatening postoperative complications were significantly low in the study group. NVI regression was higher in the study group and re-emergence was significantly lesser in the study group (<i>p</i> = 0.002). Mean postop IOP had shown an excellent reduction in IOP up to 14.25 ± 2.05 mm Hg with 1.5 ± 1 antiglaucoma drugs in ranibizumab group and 15.25 ± 2.95 mm Hg with 1.7 ± 0.87 antiglaucoma drugs in the control group at the 3-years follow-up period. Surgical success rates were comparable between the two groups at 1 and 3-year.</p><p><strong>Conclusion: </strong>Concurrent intravitreal ranibizumab along with primary AGV implantation minimizes postoperative complications, regresses NVI while accelerating stabilization of IOP and visual functions.</p><p><strong>How to cite this article: </strong>Kaushik J, Parihar JKS, Shetty R, <i>et al.</i> A Long-term Clinical Study to Evaluate AGV with Concurrent Intravitreal Ranibizumab vs Primary AGV Implantation in Cases of Refractory Neovascular Glaucoma. J Curr Glaucoma Pract 2022;16(1):41-46.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":" ","pages":"41-46"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/6e/jocgp-16-41.PMC9385393.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40348254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}